Imagine the hardest parts of late-stage dementia — the restlessness, the confusion, the aggression. Now imagine a treatment that made nearly 90% of patients better. Because that's what a new U.S. clinical trial just pulled off.
Researchers unveiled results from a trial using a specific, purified medication combining THC and CBD — the active compounds from cannabis. The headline? It dramatically reduced agitation in people with advanced dementia, outperforming a placebo by a landslide.
A Rare Win Against a Tough Foe
Dementia-related agitation is a brutal reality for patients and their caregivers. Current treatments often fall short, bringing with them a parade of unwanted side effects. Enter the LiBBY trial, which included 120 hospice-eligible individuals with Alzheimer's or other forms of dementia.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxAfter 12 weeks, an astonishing 87.2% of those receiving the cannabis-derived medication showed overall improvement. To put that in perspective, only 23.6% of the placebo group saw similar gains. Dr. Jacobo Mintzer, a co-lead investigator from the Medical University of South Carolina, called the results "extremely impressive," noting that such a high response rate is practically unheard of in dementia research.
Ten medical centers across the U.S. conducted home visits, meticulously tracking changes in agitation using a 29-behavior survey. They found that the treated group's agitation scores dropped 6.27 points more than the placebo group's after just two weeks, a difference that held strong at 12 weeks.
Not Your Dispensary's Edibles
Now, before you start eyeing your local dispensary, the researchers were quick to pump the brakes. This isn't a free pass to self-medicate with commercial cannabis products. Brigid Reynolds from Georgetown University, who also presented the findings, stressed a crucial point: the trial medication is very different from what you'd find on a shelf or online.
This was a carefully formulated, medically supervised oil suspension, with precise ratios and quality control. Commercial products, on the other hand, are a wild west of varying potency, purity, and unknown dosages. So, while the results offer a huge beacon of hope for future treatments, don't assume your recreational gummy will have the same effect — or even be safe.
Side effects in the trial, like infections or stomach issues, were similar in both the treatment and placebo groups, which is typical for this patient population. Laura, whose mother participated, noted her mom seemed happier and more connected, even without knowing if she received the real deal. Which, if you think about it, is a pretty powerful endorsement for a trial that's just scratching the surface.
